20 emerging researchers.
9 countries. 8+ funding bodies.
One fragmented field, unified.

Unlike rare bone disease — where NIAMS is the dominant NIH institute — HS has no single funding home. Researchers are funded through NIH career awards (K23, K01, R21, R01), the HS Foundation's Danby Research Grant, the European Hidradenitis Suppurativa Foundation (EHSF), ZonMw in the Netherlands, DFG in Germany, NHMRC in Australia, SNSF in Switzerland, CIHR in Canada, and substantial industry co-funding from UCB, AbbVie, Boehringer Ingelheim, Almirall, and Novartis.

​

This fragmentation means the most important emerging investigators are invisible to any single database. OniX tracked all streams simultaneously — identifying 20 non-old-guard researchers with active grants, including the first-ever HS GWAS PI (Sayed, UNC, $2.3M NIH R01), the Hippo pathway fibrosis team (Gudjonsson/van Straalen, Michigan/Erasmus, JCI 2024), and the SYK/fostamatinib clinical trial leader (Frew, UNSW, NHMRC).